Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial - Summary - MDSpire

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial

  • By

  • Hubert H. Fernandez

  • Stuart H. Isaacson

  • Robert A. Hauser

  • Pinky Agarwal

  • William Ondo

  • Ariane Park

  • Daniel Kremens

  • Matthew Leoni

  • Sridhar Duvvuri

  • Cari Combs

  • Erica Koenig

  • Ih Chang

  • Gina Pastino

  • Stacey Tringali

  • Nicole Golonski

  • Raymond Sanchez

  • Linda Harmer

  • Joey Boiser

  • Cindy Zadikoff

  • Zoltan Mari

  • May 1, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy, safety, and tolerability of flexible-dose tavapadon as an adjunctive therapy for Parkinson's Disease in levodopa-treated adults experiencing off-time fluctuations, which significantly impact patient quality of life.

Key Findings:
  • Tavapadon improved motor control and increased on-time without troublesome dyskinesia compared to placebo, with a statistically significant difference.
  • The treatment was well tolerated with a safety profile comparable to existing therapies, with no new safety concerns identified.
  • Adverse events were monitored, with a focus on impulse control disorders and other potential side effects, which were consistent with previous findings.
Interpretation:

Tavapadon represents a promising adjunctive therapy for managing motor fluctuations in Parkinson's Disease, potentially offering benefits over traditional D2/D3 receptor agonists, particularly in terms of safety profile.

Limitations:
  • The study duration was limited to 27 weeks, which may not capture long-term effects, necessitating further research.
  • The trial's exclusion criteria may limit generalizability to broader PD populations, particularly those with comorbidities.
Conclusion:

Tavapadon shows potential as a complementary therapy for Parkinson's Disease, warranting further investigation in longer-term studies to confirm its efficacy and safety.

Original Source(s)

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial

  • by Hubert H. Fernandez, Stuart H. Isaacson, Robert A. Hauser, Pinky Agarwal, William Ondo, Ariane Park, Daniel Kremens, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Erica Koenig, Ih Chang, Gina Pastino, Stacey Tringali, Nicole Golonski, Raymond Sanchez, Linda Harmer, Joey Boiser, Cindy Zadikoff, Zoltan Mari

  • May 1, 2026

Related Content

The Smart Contact Lens Evolves

New research shows how microstructured contact lenses can track eye movements with remarkable accuracy using Moiré patterns

  • May 12, 2026

  • 3 min
Editorial: AI-powered advances in diagnosis and management of movement disorders

Baptist Health Miami Neuroscience Institute Advances Parkinson’s Disease Imaging With Specialized MRI Protocol

Diagnosing Parkinson’s disease has long depended primarily on clinical expertise — careful neurologic examination, longitudinal symptom assessment and the nuanced interpretation of movement abnormalities.

  • by

  • May 11, 2026

  • 5 min